Since adding Allarity (ALLR) to the Watch List at $0.70, we are up 194%, and that ain’t bad – for exactly 4 months and one day!
The stock had first fallen from $22 to $0.70 in the previous year, when we were told about it. They’ve had four reverse splits since 2023 – so as a reminder, do not completely write off stocks that have done a (or numerous) reverse splits. The stock is actually down from $7,084,000 (post split) in January of 2022. Sorry to laugh, but OMFG!
April 25th, 2025. Adding Allarity (ALLR) $0.70, to Watch List.
This is our second big winner we’ve had from our Mergers and Acquisition expert (we’ll call him the ‘Big Wig’) who is based in Kansas City, Kansas.
His first big idea when we met in Kansas, was PharmaTher (PHRMF) which was trading at $0.04 at the time. It was a 10 bagger for us, for all of ten minutes a few weeks ago, but has since retreated to $0.30. We’re letting it ride, despite the big gain, in our Psychedelic Watch List.
Pharmather (PHRRF) Has Officially Broken Out.
Though we don’t know Allarity all that well, he said he was rolling out of Allarity (as we are) and into Oncolytics Biotech (ONCY). When Mr. Big Wig talks, people listen. At least we do! Of course previous recommendations from us or the Big Wig have no relation, inclination or indication of future performance. Nada.
Adding Oncolytics Biotech (ONCY) to 2025 Watch List.
Allarity News
The news propelling Allarity today was an FDA Fast Track Designation for their treatment of advanced ovarian cancer.
Average daily volume of 200,000 has jumped to 250 million and it’s only 11:00. What the? Where does all this volume come from?
Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer
TARPON SPRINGS, Fla., August 26, 2025 — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to stenoparib, its investigational treatment for patients with advanced ovarian cancer.
The FDA’s Fast Track designation is intended to expedite the development and review of drugs that treat serious conditions and fill an unmet medical need. This designation enables more frequent interactions with the FDA throughout the drug development process and potentially provides eligibility for accelerated approval, priority review, and rolling review if relevant criteria are met.
“We are very pleased that the FDA has granted Fast Track designation to stenoparib,” said Thomas Jensen, Chief Executive Officer of Allarity Therapeutics. “This recognition underscores the significant unmet need facing women with advanced ovarian cancer and reflects the potential of stenoparib to meaningfully improve treatment outcomes. We look forward to engaging closely with the FDA as we advance this program.”
Allarity recently began patient enrollment under a new Phase 2 clinical trial protocol evaluating stenoparib in advanced, recurrent, platinum-resistant or platinum-ineligible ovarian cancer. The first patient was enrolled in early June 2025, and several patients have already been dosed. The trial is designed to accelerate clinical development of stenoparib and its DRP® companion diagnostic and builds on prior encouraging Phase 2 data showing durable clinical benefit, including patients who remain on treatment now for over 22 months.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company’s current expectations or forecasts of future events. The words “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the regulatory advancement of stenoparib; anticipated interactions with the FDA under Fast Track designation; expected timelines and outcomes of the ongoing Phase 2 trial in advanced ovarian cancer; and the potential impact of the DRP® companion diagnostic on patient selection and treatment outcomes. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the future development and regulatory approval of stenoparib; the outcome of FDA interactions and potential reliance on Fast Track-related incentives; uncertainties in clinical trial enrollment, execution, and data interpretation; and the Company’s ability to successfully validate and deploy its DRP® companion diagnostic. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our Form 10-K annual report filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2025, available at the SEC’s website at www.sec.gov, and as well as discussions of potential risks, uncertainties and other important factors in the Company’s subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.
